Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Inhaled insulin future in doubt

  • Comment
The future of the inhaled insulin product Exubera is in doubt, after pharmaceutical giant Pfizer announced it is to cease development.

The future of the inhaled insulin product Exubera is in doubt, after pharmaceutical giant Pfizer announced it is to cease development.

It will also return marketing rights to Nektar Therapeutics, which owns the technology.

Pfizer said the product had not been accepted sufficiently by health professionals and was no longer financially sustainable because of low uptake. However, it insisted Exubera was safe.

NICE guidance says the product may be used in patients unable to inject insulin.

Simon O'Neill, director of care, information and advocacy services at Diabetes UK, said: 'We understand that because of commercial pressure this decision was necessary.

'Nevertheless, Exubera does provide an alternative treatment to insulin injections for some people with diabetes and we therefore hope this product will remain available in the future,' he said.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.